An adjuvant autologous therapeutic vaccine %28HSPPC-96%3B vi…
An adjuvant autologous therapeutic vaccine %28HSPPC-96%3B vitespen%29 versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma%3A a multicentre%2C open-label%2C randomised phase III trial.
Article, Chapter
Authors:
C. Wood
Publication:
Volume:372,
Issue:9633,
Page(s):145-154
Published:
2008
We were unable to find direct full text links for this item.